Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome

References

• Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Lucky A W, Rosenfield R L, McGuire J, Rudy S, Helke J. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62: 840–848
   PubMed Web of Science ®Google Scholar
• Moran C, Reyna R, Boots L S, Azziz R. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgens excess. Fertil Steril 2004; 81: 126–131
   PubMed Web of Science ®Google Scholar
• Ovalle F, Azziz R. Insulin resistance, the polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095–1105
   PubMed Web of Science ®Google Scholar
• Nardo L G, Rai R. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001; 15: 373–380
   PubMed Web of Science ®Google Scholar
• Barbieri R L, Makris A, Randall R W, Daniels G, Kistner R W, Ryan K J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904–910
   PubMed Web of Science ®Google Scholar
• Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 1997; 12: 1046–1047
   PubMed Web of Science ®Google Scholar
• DeFronzo R A, Goodman A M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541–549
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114–119
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876–1880
   PubMed Web of Science ®Google Scholar
• Vanky E, Kjotrod S B, Maesel A, Bjerve K S, Carlsen S M. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 459–462
   PubMed Web of Science ®Google Scholar
• Baulieu E E, Robel P. Neurosteroids: a new brain function?. J Steroid Biochem Mol Biol 1990; 37: 395–403
   PubMed Web of Science ®Google Scholar
• Paul S M, Purdy R H. Neuroactive steroids. FASEB J 1992; 6: 2311–2322
   PubMed Web of Science ®Google Scholar
• Mellon S H, Deschepper C F. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res 1993; 629: 283–292
   PubMed Web of Science ®Google Scholar
• Robel P, Baulieu E E. Neurosteroids: biosynthesis and function. Trends Endocrinol Metab 1994; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi R E, Luisi S, Palumbo M, Purdy R H, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998; 83: 2099–2103
   PubMed Web of Science ®Google Scholar
• Corpechot C, Young J, Calvel M, Wehrey C, Veltz J N, Touyer G, Mouren M, Prasad V V, Banner C, Sjovall J. Neurosteroids: 3α-hydroxy-5α-pregnan-20-one and its precursor in the brain, plasma, and steroidogenic glands of male, and female rats. Endocrinology 1993; 133: 1003–1009
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Luisi M, Malavasi B, Strucchi C, Luisi S, Casarosa E, Bernardi F, Genazzani A R, Petraglia F. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 2002; 146: 347–356
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba A J, Spaczynski R Z, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149–1154
   PubMed Web of Science ®Google Scholar
• Legro R S, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Fabbri G, Monzani A, Montanini V, Genazzani A R. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 1990; 54: 222–226
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Benatti R, Montanini V, Algeri I, Volpe A, Genazzani A R. Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 1991; 72: 1220–1225
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani A R. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 2003; 80: 1495–1501
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Pianazzi F, Volpogni C, Genazzani A R. The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 1993; 7: 33–41
   PubMed Web of Science ®Google Scholar
• Oerter K E, Guardabasso V, Rodbard D. Detection and characterization of peaks and estimation of instantaneous secretory rate for episodic pulsatile hormone secretion. Comput Biomed Res 1986; 19: 170–191
   PubMedGoogle Scholar
• Genazzani A D. Application of peak-detection programs to clinical data. Computers in endocrinology: Recent advances, V Guardabasso, D Rodbard, G Forti. Raven Press, New York 1990; 71–82
   Google Scholar
• Genazzani A D, Rodbard D. Evaluation of methods for detection of pulsatile hormone secretion: sensitivity vs. specificity. Acta Endocrinol (Copenh) 1991; 124: 295–306
   PubMedGoogle Scholar
• Guardabasso V, Genazzani A D, Veldhuis J D, Rodbard D. Objective assessment of concordance of secretory events in two endocrine time-series. Acta Endocrinol (Copenh) 1991; 124: 208–218
   PubMedGoogle Scholar
• Ibanez L, Valls C, Ferrer A, Ong K, Dunger D B, De Zengher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, non obese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 2002; 87: 2870–2874
   PubMed Web of Science ®Google Scholar
• Ibanez L, Valls C, Ferrer A, Marcos M V, Rodriguez Hierro F, De Zengher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86: 3595–3598
   PubMed Web of Science ®Google Scholar
• Taylor A E. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27: 877–902
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• La Marca A, Egbe T O, Morgante G, Paglia T, Ciani A, De Leo V. Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000; 15: 21–23
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainen H N. Metformin therapy improves the menstrual pattern with minimal endocrine metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691–696
   PubMed Web of Science ®Google Scholar
• Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenism and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654
   PubMed Web of Science ®Google Scholar
• De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: 282–285
   PubMed Web of Science ®Google Scholar
• De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633–667
   PubMed Web of Science ®Google Scholar
• Faray-Ewans L, Reyna R, Knochenhauer E S, Bartolucci A A, Azziz R. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 120–125
   PubMed Web of Science ®Google Scholar
• Adams J, Polson D W, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986; 293: 355–359
   PubMed Web of Science ®Google Scholar
• Clayton R N, Ogden V, Hodgkinson J, Worswick L, Rodin D A, Dyer S, Meade T W. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?. Clin Endocrinol (Oxf) 1992; 37: 127–134
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Petraglia F, Battaglia C, Gamba O, Volpe A, Genazzani A R. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil Steril 1997; 67: 463–468
   PubMed Web of Science ®Google Scholar
• De Leo V, La Marca A, Orvieto R, Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 1598–1600
   PubMed Web of Science ®Google Scholar
• Genazzani A D, Battaglia C, Gamba O, Petraglia F, Malavasi B, Genazzani A R. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment. J Assist Reprod Genet 2000; 17: 269–275
   PubMed Web of Science ®Google Scholar